Nordic Nanovector ASA - ESG Rating & Company Profile powered by AI
This assessment of Nordic Nanovector ASA was prepared by All Street Sevva using cutting edge AI. Scroll down to the bottom of this page for potential risks for Nordic Nanovector ASA based on sector, geography and marketcap. The page includes a questions and answers table about Nordic Nanovector ASA.
Nordic Nanovector ASA in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 7.0; made up of an environmental score of 6.0, social score of 8.0 and governance score of 5.7.
7.0
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 326 | Xencor Inc | 7.1 | High |
| 326 | iCo Therapeutics Inc | 7.1 | High |
| 355 | Nordic Nanovector ASA | 7.0 | High |
| 355 | Agile Therapeutics Inc | 7.0 | High |
| 355 | Antisense Therapeutics Ltd | 7.0 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Nordic Nanovector ASA have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Nordic Nanovector ASA disclose current and historical energy intensity?
Sign up for free to unlockDoes Nordic Nanovector ASA report the average age of the workforce?
Sign up for free to unlockDoes Nordic Nanovector ASA reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Nordic Nanovector ASA disclose its ethnicity pay gap?
Sign up for free to unlockDoes Nordic Nanovector ASA disclose cybersecurity risks?
Sign up for free to unlockDoes Nordic Nanovector ASA offer flexible work?
Sign up for free to unlockDoes Nordic Nanovector ASA have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Nordic Nanovector ASA disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Nordic Nanovector ASA conduct supply chain audits?
Sign up for free to unlockDoes Nordic Nanovector ASA disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Nordic Nanovector ASA conduct 360 degree staff reviews?
Sign up for free to unlockDoes Nordic Nanovector ASA disclose the individual responsible for D&I?
Sign up for free to unlockDoes Nordic Nanovector ASA disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Nordic Nanovector ASA disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Nordic Nanovector ASA disclose water use targets?
Sign up for free to unlockDoes Nordic Nanovector ASA have careers partnerships with academic institutions?
Sign up for free to unlockDid Nordic Nanovector ASA have a product recall in the last two years?
Sign up for free to unlockDoes Nordic Nanovector ASA disclose incidents of discrimination?
Sign up for free to unlockDoes Nordic Nanovector ASA allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Nordic Nanovector ASA issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Nordic Nanovector ASA disclose parental leave metrics?
Sign up for free to unlockDoes Nordic Nanovector ASA disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Nordic Nanovector ASA disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Nordic Nanovector ASA disclose the pay ratio of women to men?
Sign up for free to unlockDoes Nordic Nanovector ASA support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Nordic Nanovector ASA disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Nordic Nanovector ASA reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Nordic Nanovector ASA involved in embryonic stem cell research?
Sign up for free to unlockDoes Nordic Nanovector ASA disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Nordic Nanovector ASA disclose its waste policy?
Sign up for free to unlockDoes Nordic Nanovector ASA report according to TCFD requirements?
Sign up for free to unlockDoes Nordic Nanovector ASA disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Nordic Nanovector ASA disclose energy use targets?
Sign up for free to unlockDoes Nordic Nanovector ASA disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Nordic Nanovector ASA have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Nordic Nanovector ASA
These potential risks are based on the size, segment and geographies of the company.
Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutics for hematological cancers in Norway. The company's lead product candidate is Betalutin, a CD37-targeting antibody-radionuclide-conjugate, which is in Phase 2b clinical trial for the treatment of patients with non-hodgkin lymphoma. Its preclinical development product also includes Alpha37, an anti-CD37 alphaparticle emitting radioimmunoconjugate for treating chronic lymphatic leukemia. The company has collaboration agreements with Paul Scherrer Institute; ArevaMed; LegoChem Bio; and Heidelberg Pharma. It also has a research collaboration with the University of Pennsylvania to generate a CD37-targeting CAR-T cell approach as a treatment for patients with B-cell malignancies. The company was formerly known as Nordic Nanovector AS and changed its name to Nordic Nanovector ASA in 2014. Nordic Nanovector ASA was incorporated in 2009 and is headquartered in Oslo, Norway.